-
1.发明公开CRYSTALLINE FORM OF 1´-(1-METHYLETHYL)- 4´-[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5´-METHYL-1H-PYRAZOL-3´-O-beta-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS 审中-公开4' - [（2-氟-4-甲氧基苯基）甲基] -5'-甲基-1H-吡唑-3'-O-BETA-D-吡喃葡糖苷，METHODS - 的1,1'-（1-甲基乙基）结晶形式 其制备和它们在药品生产
公开(公告)号：EP1976859A1
公开(公告)日：2008-10-08
申请号：EP07703756.2
申请日：2007-01-10
申请人： Boehringer Ingelheim International GmbH , Ajinomoto Co., Inc. , Boehringer Ingelheim Pharma GmbH & Co. KG
发明人： KRAEMER, Gerd , MARTIN, Hans-Jürgen , ADELGOSS, Gebhard , DUGI, Klaus , DURAN, Adil , EICKELMANN, Peter , MAIER, Steffen , PINNETTI, Sabine , RITTER, Regine , SCHILCHER, Gebhard , STREICHER, Ruediger , THOMAS, Leo
IPC分类号： C07H17/02 , A61K31/7056 , A61P3/10
CPC分类号： C07H17/02
摘要： The invention relates to a crystalline form of 1´-(1-methylethyl)- 4´-[(2-fluoro-4- methoxyphenyl)methyl]-5´-methyl-1H-pyrazol-3´-O-β-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.
-
2.发明公开COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS 审中-公开与SGLT-2抑制剂及其药物组合物联合治疗
公开(公告)号：EP3037095A3
公开(公告)日：2016-11-16
申请号：EP16152228.9
申请日：2007-11-08
IPC分类号： A61K31/341 , A61K31/70 , A61P3/00 , A61P3/10 , A61K31/351 , A61K31/155 , A61K45/06 , A61K38/28
CPC分类号： A61K31/7048 , A61K9/02 , A61K9/20 , A61K9/48 , A61K31/155 , A61K31/341 , A61K31/351 , A61K31/70 , A61K38/26 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome.
-
公开(公告)号：EP2015754B1
公开(公告)日：2014-04-09
申请号：EP07728723.3
申请日：2007-05-03
发明人： DUGI, Klaus , HIMMELSBACH, Frank , MARK, Michael
IPC分类号： A61K31/522 , A61K31/4985 , A61P3/10 , A61P9/04
CPC分类号： A61K31/522 , A61K31/155 , A61K31/197 , A61K31/4184 , A61K31/4985 , A61K31/5025 , A61K31/52 , A61K31/7048 , A61K45/06 , Y10S514/866
-
公开(公告)号：EP4104838A1
公开(公告)日：2022-12-21
申请号：EP22184210.7
申请日：2007-05-03
发明人： DUGI, Klaus , HIMMELSBACH, Frank , MARK, Michael
IPC分类号： A61K31/522 , A61K31/4985 , A61P3/10 , A61P9/04
摘要： Beschrieben wird die Verwendung ausgewählter DPP IV Inhibitoren zur Behandlung physiologischer Funktionsstörungen sowie zur Reduktion des Risikos eines Eintretens solcher Funktionsstörungen in gefährdeten Patientengruppen. Zusätzlich wird die Verwendung der genannten DPP IV Inhibitoren in Kombination mit weiteren Wirkstoffen beschrieben, wodurch verbesserte Behandlungsergebnisse erzielt werden können. Diese Verwendungen lassen sich zur Herstellung entsprechender Arzneimittel nutzen.
-
5.发明公开COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS 审中-公开KOMBINATIONSTHERAPIE MIT SGLT-2-INHIBITOREN UND DEREN PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
公开(公告)号：EP3037095A2
公开(公告)日：2016-06-29
申请号：EP16152228.9
申请日：2007-11-08
IPC分类号： A61K31/341 , A61K31/70 , A61P3/00 , A61P3/10 , A61K31/351 , A61K31/155 , A61K45/06
CPC分类号： A61K31/7048 , A61K9/02 , A61K9/20 , A61K9/48 , A61K31/155 , A61K31/341 , A61K31/351 , A61K31/70 , A61K38/26 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome.
摘要翻译： 本发明涉及由一种或多种与一种或多种治疗剂组合的一种或多种SGLT-2抑制剂化合物组成的药物组合物，其适用于治疗包括1型糖尿病，2型糖尿病， 葡萄糖耐量降低，高血糖症，餐后高血糖症，超重，肥胖，包括I型肥胖，II类肥胖，III级肥胖，内脏肥胖和腹部肥胖，以及代谢综合征。
-
6.发明公开COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS 审中-公开与SGLT-2抑制剂及其药物组合物联合治疗
公开(公告)号：EP2081569A2
公开(公告)日：2009-07-29
申请号：EP07822331.0
申请日：2007-11-08
IPC分类号： A61K31/341 , A61K31/70 , A61P3/00 , A61P3/10
CPC分类号： A61K31/7048 , A61K9/02 , A61K9/20 , A61K9/48 , A61K31/155 , A61K31/341 , A61K31/351 , A61K31/70 , A61K38/26 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome.
-
公开(公告)号：EP2015754A2
公开(公告)日：2009-01-21
申请号：EP07728723.3
申请日：2007-05-03
发明人： DUGI, Klaus , HIMMELSBACH, Frank , MARK, Michael
IPC分类号： A61K31/522 , A61K31/4985 , A61P3/10 , A61P9/04
CPC分类号： A61K31/522 , A61K31/155 , A61K31/197 , A61K31/4184 , A61K31/4985 , A61K31/5025 , A61K31/52 , A61K31/7048 , A61K45/06 , Y10S514/866
摘要： Disclosed is the use of selected DPP-IV inhibitors for treating physiological functional disorders and reducing the risk of at-risk patient groups developing such functional disorders. Also disclosed is the use of said DPP-IV inhibitors in combination with other agents such that improved treatment results can be obtained. Said uses can be employed for producing corresponding medicaments.
-
8.发明公开METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES 审中-公开FOR预防方法和代谢性疾病和新吡-O-糖苷衍生物的治疗
公开(公告)号：EP1912656A2
公开(公告)日：2008-04-23
申请号：EP06778010.6
申请日：2006-07-27
发明人： HIMMELSBACH, Frank , MAIER, Roland , EICKELMANN, Peter , THOMAS, Leo , BARSOUMIAN, Edward, Leon , DUGI, Klaus , PINNETTI, Sabine , RITTER, Regine , STREICHER, Ruediger , FUJITA, Koichi , HATANAKA, Toshihiro , ISHIDA, Nozomu , MAEZONO, Katsumi , OHSUMI, Koji
IPC分类号： A61K31/7056 , C07H17/02 , A61P3/04 , A61P3/10
CPC分类号： A61K31/7056 , C07H17/02
摘要： The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for preventing or treating of complications of diabetes mellitus, for reducing the weight, for preventing or treating the degeneration of pancreatic beta cells, for treating hyperinsulinemia and insulin resistance and diabetes type 1, in patients in need thereof by administering a pharmaceutical composition comprising a pyrazole-O-glycoside as defined in claim 1 , or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：EP1945212A1
公开(公告)日：2008-07-23
申请号：EP06806641.4
申请日：2006-10-31
CPC分类号： A61K45/06 , A61K31/46 , Y10S514/866
摘要： The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2, 3 -disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of diabetic patients.
-
10.发明公开TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN 审中-公开BEHANDLUNG VON基因治疗糖尿病 - 麻醉药DPP-IV-HEMMERN WIE ETWA LINAGLIPTIN
公开(公告)号：EP2504002A1
公开(公告)日：2012-10-03
申请号：EP10785054.7
申请日：2010-11-26
发明人： DUGI, Klaus , GRAEFE-MODY, Eva, Ulrike , MARK, Michael , WOERLE, Hans-Juergen , ZIMDAHL-GELLING, Heike
IPC分类号： A61K31/155 , A61K31/44 , A61K31/519 , A61K45/06
摘要： The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
摘要翻译： 本发明涉及用于预防或治疗代谢紊乱和相关病症的方法，例如在某些患者组中。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.021 秒)
